Patents by Inventor Paul R. Fatheree

Paul R. Fatheree has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE
    Publication number: 20210269436
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: February 12, 2021
    Publication date: September 2, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN
  • 2-AZABICYCLO HEXANE JAK INHIBITOR COMPOUND
    Publication number: 20210206764
    Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes useful for preparing the compound.
    Type: Application
    Filed: March 1, 2021
    Publication date: July 8, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, Lan Jiang
  • JAK KINASE INHIBITOR COMPOUNDS FOR TREATMENT OF RESPIRATORY DISEASE
    Publication number: 20210130351
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: January 5, 2021
    Publication date: May 6, 2021
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Gary E.L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Anne-Marie Beausoleil
  • IL-17A MODULATORS AND USES THEREOF
    Publication number: 20210101886
    Abstract: The disclosure herein provides compounds and pharmaceutical compositions for the modulation of IL-17A useful for the treatment of inflammatory conditions, such as psoriasis.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 8, 2021
    Inventors: Paul R. FATHEREE, Martin S. LINSELL, John R. JACOBSEN, Wouter A. VAN DER LINDEN, Timothy J. CHURCH, Claudio AQUINO, Margot G. PAULICK
  • 2-azabicyclo hexane JAK inhibitor compound
    Patent number: 10968222
    Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes useful for preparing the compound.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: April 6, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, Lan Jiang
  • JAK inhibitors containing a 4-membered heterocyclic amide
    Patent number: 10954237
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: March 23, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden
  • JAK kinase inhibitor compounds for treatment of respiratory disease
    Patent number: 10913740
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: February 9, 2021
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Gary E. L. Brandt, Noah Benjamin, Marta Dabros, Venkat R. Thalladi
  • IL-17 Ligands And Uses Thereof
    Publication number: 20200247785
    Abstract: Provided herein are novel ligands and pharmaceutical compositions thereof which modulate IL-17A. Also provided are methods for preparing the IL-17A modulators. Such compounds may be useful in the treatment and/or prevention of, for example, inflammation, cancer or autoimmune disease.
    Type: Application
    Filed: February 6, 2020
    Publication date: August 6, 2020
    Inventors: Paul R. Fatheree, Martin S. Linsell, John R. Jacobsen, Wouter Van der Linden, Timothy J. Church, Claudio Aquino, Margot Paulick
  • JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE
    Publication number: 20200216447
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: December 3, 2019
    Publication date: July 9, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN
  • FUSED IMIDAZO-PIPERIDINE JAK INHIBITORS
    Publication number: 20200181141
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: November 11, 2019
    Publication date: June 11, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: PAUL R. FATHEREE, GARY E.L. BRANDT, CAMERON SMITH, STEVEN D.E. SULLIVAN, LORI JEAN VAN ORDEN
  • 2-AZABICYCLO HEXANE JAK INHIBITOR COMPOUND
    Publication number: 20200131178
    Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes useful for preparing the compound.
    Type: Application
    Filed: October 18, 2019
    Publication date: April 30, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, Lan Jiang
  • JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease
    Publication number: 20200087303
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: November 20, 2019
    Publication date: March 19, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Gary E.L. Brandt, Noah Benjamin, Marta Dabros, Venkat R. Thalladi
  • PYRIMIDINE COMPOUNDS AS JAK KINASE INHIBITORS
    Publication number: 20200046709
    Abstract: The invention provides compounds of formula (I): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of JAK kinases. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat gastrointestinal and other inflammatory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 13, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Ryan Hudson, Jennifer Kozak, Melissa Fleury, Paul R. Fatheree, Anne-Marie Beausoleil, Dante D. Podesto, Xiaojun Huang
  • FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND
    Publication number: 20200046719
    Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 13, 2020
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: ROBERT MURRAY MCKINNELL, VENKAT R. THALLADI, HAO ZHANG, PAUL R. FATHEREE, LAN JIANG, MARTA DABROS, JERRY NZEREM
  • JAK inhibitors containing a 4-membered heterocyclic amide
    Patent number: 10550118
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: July 15, 2019
    Date of Patent: February 4, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
  • JAK kinase inhibitor compounds for treatment of respiratory disease
    Patent number: 10526330
    Abstract: The invention provides compounds of formula (I): wherein X is and the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: December 10, 2018
    Date of Patent: January 7, 2020
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, John R. Jacobsen, Gary E. L. Brandt, Melissa Fleury, Lan Jiang, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Anne-Marie Beausoleil
  • Fused imidazo-piperidine JAK inhibitors
    Patent number: 10519153
    Abstract: The invention provides compounds of formula (I): where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: December 31, 2019
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
  • Fused imidazo-piperidine JAK inhibitor compound
    Patent number: 10493077
    Abstract: The invention provides a compound of formula 1 or a pharmaceutically-acceptable salt thereof, that is useful as a JAK inhibitor. The invention also provides crystalline forms of the compound, pharmaceutical compositions comprising the compound, methods of using the compound to treat diseases amenable to a JAK inhibitor, and processes and intermediates useful for preparing the compound.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: December 3, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, Lan Jiang, Venkat R. Thalladi, Marta Dabros, Jerry Nzerem
  • JAK INHIBITORS CONTAINING A 4-MEMBERED HETEROCYCLIC AMIDE
    Publication number: 20190337945
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: July 15, 2019
    Publication date: November 7, 2019
    Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. FATHEREE, Gary E.L. Brandt, Cameron Smith, Steven D.E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater
  • JAK inhibitors containing a 4-membered heterocyclic amide
    Patent number: 10392386
    Abstract: The invention provides compounds of formula (I): which contain a 4-membered heterocyclic amide, where the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are useful as JAK kinase inhibitors. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat respiratory diseases, and processes and intermediates useful for preparing such compounds.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: August 27, 2019
    Assignee: THERAVANCE BIOPHARMA R&D IP, LLC
    Inventors: Paul R. Fatheree, Gary E. L. Brandt, Cameron Smith, Steven D. E. Sullivan, Lori Jean Van Orden, Melanie A. Kleinschek, Glenn D. Crater